PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA)

Solid Tumors Clinical Trial

— PANAMA  

Official title:

A Phase 1 Open-Label Study of the Safety, Tolerability and Efficacy of KPT-9274, a Dual Inhibitor of PAK4 and NAMPT, in Patients With Advanced Solid Malignancies or Non-Hodgkin's Lymphoma

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02702492
• Other study ID #: KCP-9274-901
• Status: Terminated
• Phase: Phase 1
• Start date: June 2016
• Est. completion date: June 1, 2021

Study information

• Verified date: January 2023
• Source: Karyopharm Therapeutics Inc
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will evaluate the safety, tolerability, and efficacy of oral KPT-9274 for the treatment of patients with advanced solid malignancies or non-Hodgkin's lymphoma (NHL). Currently enrolling melanoma patients in combination with nivolumab, only.

Description:

This is a first-in-human, multi-center, open-label clinical study with separate Dose Escalation and Expansion Phases to assess preliminary safety, tolerability, and efficacy of KPT-9274, a dual inhibitor of PAK4 and NAMPT, in patients with advanced solid malignancies (including sarcoma, colon, lung, melanoma, etc.) or NHL for which all standard therapeutic options considered useful by the investigator have been exhausted.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 60
• Est. completion date: June 1, 2021
• Est. primary completion date: February 1, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Participants must meet all of the following inclusion criteria to be eligible to enroll in the Part C of this study.

1. Should have unresectable advanced, recurrent or metastatic melanoma and must have objective and measurable melanoma by RECIST 1.1 after disease progression on a prior anti-PD-1 or anti-PD-L1 therapy.

2. ECOG performance status of = 2.

3. Life expectancy of = 3 months.

4. Adequate hepatic function:

• Total bilirubin < 1.5 times the ULN (except participants with Gilbert's syndrome [hereditary indirect hyperbilirubinemia] who must have a total bilirubin of = 3 times ULN),

• AST and ALT = 2.5 times ULN (except participants with known liver involvement of their advanced solid malignancy who must have an AST and ALT = 5.0 times ULN).

5. Adequate renal function:

• Estimated creatinine clearance of = 60 mL/min, calculated using the formula of Cockroft and Gault (140-Age) Mass (kg)/(72 creatinine mg/dL); multiply by 0.85 if female.

6. Adequate hematopoietic function:

• Total WBC count = 1500/mm³, ANC = 1000/mm³, Hb = 10.0 g/dL, platelet count = 100,000/mm³

Exclusion Criteria:

Participants meeting any of the following exclusion criteria are not eligible to enroll in this study.

1. = 2 weeks since the last prior therapeutic regimen for melanoma. Palliative steroids for disease related symptoms < 7 days prior to C1D1, unless physiologic doses of steroids are used.

2. Have not recovered or stabilized (Gr 1 or to their baseline for non-hematologic toxicities, = Gr 2 or to their baseline for hematologic toxicities) from toxicities related to their previous treatment except for alopecia.

3. Untreated CNS disease or leptomeningeal involvement are excluded. Participants without active brain or leptomeningeal metastases after prior treatment with local therapies are eligible provided that the treatment had been done = 2 weeks prior to enrollment.

4. Active infection with completion of therapeutic antibiotics, antivirals, or antifungals within one week prior to C1D1. Prophylactic antibiotics, antivirals or antifungals are permitted.

5. Significantly diseased or obstructed gastrointestinal tract or uncontrolled vomiting or diarrhea that could interfere with the absorption of KPT-9274.

6. Active peptic ulcer disease or other active gastrointestinal bleeds.

7. Requiring treatment with corticosteroids at doses higher than substitute therapy (> 10 mg prednisone), are unstable with substitute hormonal therapy, or are deemed to be likely to re-occur by the treating physician when administered nivolumab.

Related Conditions & MeSH terms

• Neoplasms
• NHL
• Solid Tumors

Intervention

Drug:
• KPT-9274

• Niacin ER

• Nivolumab

Locations

Country	Name	City	State
Canada	Princess Margaret Hospital	Toronto	Ontario
United States	University of Colorado Cancer Center	Aurora	Colorado
United States	MD Anderson Cancer Center	Houston	Texas
United States	UCLA Health	Los Angeles	California
United States	Vanderbilt-Ingram Cancer Center	Nashville	Tennessee
United States	NYU-Laura & Isaac Perlmutter Cancer Center	New York	New York
United States	Mayo Clinic Rochester	Rochester	Minnesota
United States	Georgetown University, Lombardi Comprehensive Cancer Center	Washington	District of Columbia

Sponsors (1)

Lead Sponsor	Collaborator
Karyopharm Therapeutics Inc

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum tolerated dose (MTD) for KPT-9274 administered alone and with co-administration of niacin ER (extended release) (vitamin B3/nicotinic acid)	Parts A & B: MTD will be based on the assessment of dose limiting toxicities (DLTs) during the first cycle of therapy and will be defined as the highest dose at which =1 participant out of 6 (or 0 out of 3) experiences DLTs within Cycle 1.	Approximately 4 weeks
Primary	Maximum tolerated dose (MTD) for KPT-9274 co-administered with nivolumab	Part C: MTD will be based on the assessment of dose limiting toxicities (DLTs) during the first cycle of therapy and will be defined as the highest dose at which = 1 participant out of 6 (or 0 out of 3) experiences DLTs within Cycle 1.	Approximately 4 weeks